当前位置:
X-MOL 学术
›
Nat. Biotechnol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Editor’s pick: Switch Therapeutics
Nature Biotechnology ( IF 33.1 ) Pub Date : 2024-10-14 , DOI: 10.1038/s41587-024-02423-9
Nature Biotechnology ( IF 33.1 ) Pub Date : 2024-10-14 , DOI: 10.1038/s41587-024-02423-9
Each year, Nature Biotechnology highlights companies that have received sizeable early-stage funding in the previous year. Switch Therapeutics is rethinking cell-type specificity, building precision RNAi therapeutics for the brain.
中文翻译:
编辑推荐:Switch Therapeutics
每年,Nature Biotechnology 都会突出那些在上一年获得大量早期资金的公司。Switch Therapeutics 正在重新思考细胞类型特异性,为大脑构建精准 RNAi 疗法。
更新日期:2024-10-15
中文翻译:
编辑推荐:Switch Therapeutics
每年,Nature Biotechnology 都会突出那些在上一年获得大量早期资金的公司。Switch Therapeutics 正在重新思考细胞类型特异性,为大脑构建精准 RNAi 疗法。